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http://www.biomedcentral.com/1472-6882/14/35RESEARCH ARTICLE Open AccessAnti-osteoclastogenic activity of matairesinol via
suppression of p38/ERK-NFATc1 signaling axis
Sik-Won Choi1†, Kie-In Park2†, Jeong-Tae Yeon3, Byung Jun Ryu1, Kwang-Jin Kim3 and Seong Hwan Kim1*Abstract
Background: Matairesinol is a plant lignan present in a wide variety of foodstuffs such as seeds, vegetables and
fruits. It has various biological functions including anti-angiogenic, anti-cancer and anti-fungal activities, but its
anti-osteoporotic activity, if any, is unknown.
Methods: For osteoclast differentiation, primary mouse bone marrow-derived macrophage cells (BMMs) were
cultured for 4 days in the presence of RANKL and M-CSF with the vehicle (DMSO) or matairesinol. Cell cytotoxicity
was examined by CCK-8 assay. Gene expression of NFATc1, TRAP, OSCAR, v-ATPasev0d2 were observed in the
presence or absence of matairesinol (10 μM) for the indicated times. For evaluating the involvement of NFATc1 in
the anti-osteoclastogenic action of matairesinol, BMMs were infected with pMX-IRES-GFP or pMX-IRES-CA-NFATc1-
GFP for 8 h with polybrene, and then infected BMMs were cultured with M-CSF and RANKL for 4 days in the
presence or absence of matairesinol (10 μM). MAPK signaling activation was examined by immunoblotting. For
measuring the resorptive activity of mature osteoclasts, osteoclasts and osteoblasts were co-cultured on BioCoat
Osteologic MultiTest slides, and treated with matairesinol for 24 h.
Result: Here we show that matairesinol dose-dependently inhibited the RANKL-induced differentiation of BMMs
into osteoclasts by downregulating RANKL-induced expression and activity of NFATc1. Ectopic overexpression of
NFATc1 blunted the anti-osteoclastogenic effect of matairesinol implicating NFATc1 in the action of matairesinol.
Additionally, matairesinol blocked the RANKL-induced activation of p38 and ERK in BMMs, but had no effect on
bone resorption activity in mature osteoclasts.
Conclusion: Taken together, our results suggest that the anti-osteoporotic activity of matairesinol could arise from
its anti-osteoclastogenic potential via p38/ERK-NFATc1 signaling, but not by way of anti-resorptive action.
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Bone is a highly dynamic tissue continuously remodeled
by osteoclasts and osteoblasts, which are responsible for
bone resorption and bone formation, respectively [1].
The delicate balance between osteoclast-mediated bone
destruction and osteoblast-mediated bone formation is
important for maintaining bone mineral density.
Multinucleated osteoclasts are formed and functional-
ized by the fusion of macrophage precursor cells. Specific-
ally, excessive bone resorption by overactivated osteoclasts* Correspondence: hwan@krict.re.kr
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reproduction in any medium, provided the oris involved in several lytic bone diseases, such as osteopor-
osis, periodontal disease and rheumatoid arthritis [2,3].
Osteoporosis is a metabolic disease characterized by
decreased bone mass and an increased risk of skeletal
fracture and is widely recognized as a major public
health problem in an aging society [4]. Several anti-
resorptive agents such as bisphosphonates, calcitonin
and estrogen have been developed to treat osteoporosis,
but each one has side effects including induction of
breast cancer, osteonecrosis and vaginal bleeding [5,6].
Thus, a much safer therapeutic strategy for preventing
and/or treating lytic bone diseases including osteopor-
osis is required.
Natural product-derived small molecules have been
used as therapeutic agents for preventing and curing ad. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tochemicals elaborated from two phenylpropanoid units
in plants and are present in a wide variety of plant food-
stuffs including seeds, vegetables, and fruits [9,10].
Matairesinol (Figure 1A), a dibenzylbutyrolactone lignan,
has been reported to possess anti-oxidative, estrogenic,
or anti-estrogenic activities and reduce the risk of
hormone-dependent cancer [11]. However, the detailed
anti-osteoporotic activity and mechanism of matairesinol
has not been explored. Therefore, we examined the
in vitro effect of matairesinol on the receptor activator
of nuclear factor-κB ligand (RANKL)-induced osteoclast




Penicillin, streptomycin, cell culture medium, and fetal
bovine serum (FBS) were purchased from Invitrogen Life
Technologies. Mouse soluble macrophage-colony stimu-
lating factor (M-CSF) and RANKL were purchased from
R&D Systems. The CCK-8 assay kit was purchased from
Dojindo Molecular Technologies. Antibodies against nu-
clear factor of activated T cells (NFAT)c1, c-Fos, and
actin were purchased from Santa Cruz BiotechnologyFigure 1 Matairesinol inhibits RANKL-mediated osteoclast differentiat
in the presence of RANKL (10 ng/ml) and M-CSF (30 ng/ml) with the vehic
by TRAP staining. (C) TRAP-positive multinuclear cells (MNCs) were counted
measured. ###, P < 0.001 (versus the negative control); *, P < 0.05; **, P < 0.
matairesinol on the viability of BMMs was evaluated using the CCK-8 assayand antibodies against MAP kinases from Cell Signaling
Technology. Matairesinol was purchased from Sigma-
Aldrich and dissolved in DMSO (dimethylsulfoxide;
Sigma-Aldrich).
Preparation of osteoclast precursor cells
All experiments were carried out as described in a previ-
ous study, with modifications [12]. All animal proce-
dures were performed according to the guide for the
Institutional Animal Care and Use Committee of the
Korea Research Institute of Chemical Technology
(Protocol ID No. 7D-M1). Five-week-old male ICR
(Damul Science Co. Deajeon, Korea) were maintained in
a room illuminated daily from 07:00 to 19:00 (12:12 h
light/dark cycle), with controlled temperature (23 ± 1°C)
and ventilation (10–12 times per hour), and humidity
was maintained at 55 ± 5% with free access to a standard
animal diet and tap water. Bone marrow cells were ob-
tained from five-week-old male ICR mice by flushing fe-
murs and tibias with α-MEM-containing antibiotics (100
units/ml penicillin, 100 μg/ml streptomycin). Bone mar-
row cells were cultured on culture dishes for 1 day in
α-MEM containing 10% FBS and M-CSF (10 ng/ml).
Non-adherent bone marrow cells were plated on Petri
dishes and cultured for 3 days in the presence of M-CSFion. (A) Structure of matairesinol. (B) BMMs were cultured for 4 days
le (DMSO) or matairesinol. Multinucleated osteoclasts were visualized
. **, P < 0.01; ***, P < 0.001 (versus the control). (D) TRAP activity was
01; ***, P < 0.001 (versus the RANKL-treated control). (E) Effect of
.
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adherent cells were used as bone marrow-derived mac-
rophages (BMMs).
Osteoclast cell culture and osteoclast differentiation
BMMs were maintained in α-MEM supplemented with
10% FBS, 100 units/ml penicillin, and 100 μg/ml strepto-
mycin. The medium was changed every 3 days in a hu-
midified atmosphere of 5% CO2 at 37°C. To differentiate
osteoclasts from BMMs, BMMs (1 × 104 cells/well in a
96-well plate) were cultured with M-CSF (30 ng/ml) and
RANKL (10 ng/ml). After 3 to 4 days, multinucleated
osteoclasts were observed.
Cell viability assay
BMMs were plated in a 96-well plate at a density of 1 ×
104 cells/well in triplicate. After being treated with M-
CSF (30 ng/ml) and matairesinol, cells were incubated
for 3 days, and cell viability was measured using CCK-8
according to the manufacturer’s protocol.
TRAP staining and activity assay
Mature osteoclasts were visualized by staining tartrate-
resistant acid phosphatase (TRAP), a biomarker of
osteoclast differentiation. Briefly, multinucleated osteo-
clasts were fixed with 3.7% formalin for 10 min, perme-
abilized with 0.1% Triton X-100 for 10 min, and stained
with TRAP solution (Sigma-Aldrich). TRAP-positive
multinucleated osteoclasts (MNC; nuclear ≥3) were
counted. To measure TRAP activity, multinucleated os-
teoclasts were fixed in 3.7% formalin for 5 min, perme-
abilized with 0.1% Triton X-100 for 10 min, and treated
with TRAP buffer (100 mM sodium citrate, pH 5.0,
50 mM sodium tartrate) containing 3 mM p-nitrophenyl
phosphate (Sigma-Aldrich) at 37°C for 5 min. Reaction
mixtures in the wells were transferred to new plates con-
taining an equal volume of 0.1 N NaOH, and optical
density values were determined at 405 nm.
RNA isolation and RT-PCR
Total RNA was isolated with TRIzol reagent (Invitrogen)
according to the manufacturer’s recommended protocol.
Reverse transcription was performed with 1 μg of RNA
using oligo(dT) primers, dNTP, buffer, DTT, RNase
inhibitor, and SuperScript II reverse transcriptaseTable 1 Primer sequences used in this study





GAPDH ACCACAGTCCATGCCATCAC(Invitrogen). The cDNA was amplified using a TOPsim-
ple DryMIX premix PCR kit (Enzynomics). Table 1 lists
the primer sets used in this study. PCR products were
electrophoresed on a 1% agarose gel stained with eth-
idium bromide.
Western blot analysis
Cultured cells were washed with ice-cold phosphate-
buffered saline (PBS) and lysed in lysis buffer (50 mM
Tris–HCl, 150 mM NaCl, 5 mM EDTA, 1% Triton X-
100, 1 mM sodium fluoride, 1 mM sodium vanadate,
and 1% deoxycholate) containing protease inhibitors.
Lysates were boiled in sodium dodecyl sulfate (SDS)
sample buffer for 5 min, subjected to 10% or 12% SDS-
polyacrylamide gel electrophoresis, and transferred to a
polyvinylidene difluoride (PVDF) membrane (Millipore).
Then, the transferred PVDF membrane was then washed
with TBST (10 mM Tris–HCl, pH 7.5, 150 mM NaCl,
0.1% Tween 20) and incubated in the blocking TBST,
with 5% skim milk. The membrane was probed with the
indicated primary antibody, washed three times for
30 min, incubated with secondary antibody conjugated
to horseradish peroxidase for 2 h, and washed three
times for 30 min. Membranes were developed with
SuperSignal West Femto Maximum Sensitivity Substrate
(Pierce) using the LAS-3000 luminescent image analyzer
(Fuji Photo Film Co., Ltd., Japan).
Retrovirus preparation and infection
Retrovirus packaging was described previously [13]. In
brief, to isolate the retrovirus, pMX-IRES-GFP (the con-
trol retrovirus vector encoding GFP, green fluorescent
protein) and pMX containing constitutively active (CA)-
NFATc1 were transiently transfected into Plat-E cells
(platinum-E retrovirus packaging cell line; Cell Biolabs,
Inc.) with Lipofectamine 2000 (Invitrogen, USA) accord-
ing to the manufacturer’s protocol. Viral supernatant
was collected from the culture media 48 h after transfec-
tion. BMMs were incubated with viral supernatant in the
presence of polybrene (10 μg/ml) for 8 h. The infection
efficiency of the retrovirus was determined by GFP ex-
pression and was always greater than 80%. After infec-
tion, BMMs were induced to differentiate in the
presence of M-CSF (30 ng/ml) and RANKL (10 ng/ml)






Figure 2 Matairesinol inhibits RANKL-induced expression of
NFATc1. (A) BMMs were stimulated with RANKL (10 ng/ml) and
M-CSF (30 ng/ml) in the presence or absence of matairesinol
(10 μM) for the indicated times. Total RNA was then isolated using
TRIzol reagent, and mRNA expression levels were evaluated by
RT-PCR. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was
used as the internal control. (B) Effect of matairesinol on protein
expression level of NFATc1 was evaluated by Western blot analysis.
Actin was used as the internal control.
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Mature osteoclasts were prepared by isolating osteo-
blasts from the calvariae of newborn mice by serial di-
gestion in collagenase (Gibco, Paisley, UK), as previously
described [14]. Bone marrow cells were isolated as de-
scribed above. Osteoblasts and bone marrow cells were
co-cultured on a collagen-coated 90-mm dish in the
presence of 1α, 25-dihydroxyvitamin D3, prostaglandin
E2 for 6 days. Co-cultured cells were detached from the
collagen-coated dishes, re-plated on BioCoat Osteologic
MultiTest slides in a 96-well plate, and treated with
matairesinol for 24 h. Cells on these slides were stained
for TRAP and photographed under a light microscope at
40× magnification. For observation of resorption pits,
the slides were washed with PBS and treated with 5% so-
dium hypochlorite for 5 min. After the plate was washed
with PBS buffer and dried it, it was photographed under
a light microscope. Quantification of resorbed areas was
performed using the ImageJ program.
Statistical analysis
All quantitative values are presented as mean ± standard
deviation. Each experiment in triplicate was performed
three to five times, and the figures show results from
one representative experiment. Statistical differences
were analyzed using the Student’s t-test, and a value of
p < 0.05 was considered significant.
Results
Matairesinol inhibits RANKL-induced osteoclast
differentiation
To determine the effect of matairesinol on RANKL-
induced osteoclast differentiation, BMMs were incubated
with matairesinol followed by RANKL treatment.
RANKL induced numerous TRAP-positive multinucle-
ated osteoclasts from BMM, but matairesinol inhibited
the formation of TRAP-positive multinucleated cells in a
dose-dependent manner (Figure 1B, C). Matairesinol
also significantly decreased TRAP activity (Figure 1D).
To exclude the possibility that the inhibitory effect of
matairesinol on osteoclast differentiation might arise
from its cytotoxicity per se, its effect on the survival of
BMMs was further evaluated. As shown in Figure 1E,
matairesinol did not exhibit any cytotoxicity at the con-
centrations used in this study.
Matairesinol inhibits RANKL-induced expression of
NFATc1
The inhibitory effect of matairesinol on osteoclast differ-
entiation was confirmed by evaluation of expression of
several osteoclastogenesis-associated genes including
transcriptional factors required for osteoclast differenti-
ation. As shown in Figure 2A, RANKL strongly induced
the mRNA expression of NFATc1, but matairesinolattenuated its induction. Matairesinol also strongly at-
tenuated the mRNA expression of NFATc1-dependent
genes such as TRAP, osteoclast-associated immuno-
globulin-like receptor (OSCAR), and the d2 isoform of
vacuolar ATPase V0 domain (Atp6v0d2). Western blot
analysis further revealed that matairesinol exposure re-
sulted in decreased RANKL-mediated induction of
NFATc1 protein (Figure 2B). Taken together, these
results suggested that the inhibitory effect of matairesi-
nol on osteoclast differentiation could arise from its
potential to inhibit the expression of NFATc1, the
key major transcription factor required for osteoclast
differentiation.
Overexpression of NFATc1 restores matairesinol-mediated
inhibition of osteoclast differentiation
To investigate whether suppression of NFATc1 expres-
sion is crucial for the anti-osteoclastogenic activity of
matairesinol, the effect of NFATc1 overexpression on
matairesinol-mediated inhibition of osteoclast differenti-
ation was evaluated. When BMMs were infected with
retrovirus harboring the control GFP or a constitutively
active (CA)-NFATc1-GFP gene expression construct, the
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the control GFP and those with CA-NFATc1-GFP
(Figure 3A). Consistent with the result shown in
Figure 1B, the TRAP-positive multinucleated osteoclasts
were less formed in the presence of matairesinol (upper
images in Figure 3B), but the forced expression of
NFATc1 dramatically overcame the anti-osteoclastogenic
action of matairesinol (bottom images in Figure 3B). The
restoring effect of NFATc1 overexpression on the
matairesinol-induced inhibition of osteoclast differenti-
ation was also confirmed by counting the number of
multinucleated osteoclasts and measuring the activity of
TRAP (Figure 3C, D). Taken together, these results con-
firmed our hypothesis that matairesinol could inhibit
RANKL-induced osteoclast differentiation by suppressing
the expression of NFATc1.Figure 3 NFATc1 overexpression restores matairesinol-mediated inhib
pMX-IRES-GFP (GFP) or pMX-IRES-CA-NFATc1-GFP (CA-NFATc1-GFP) for 8 h
(30 ng/ml) and RANKL (10 ng/ml) for 4 days in the presence or absence of
visualized under a fluorescence microscope. (B) BMMs were infected with G
After 4 days, mature TRAP-positive multinucleated osteoclasts were visualiz
osteoclasts. (D) TRAP activity was measured at 405 nm.Matairesinol inhibits RANKL-induced phosphorylation of
p38 and ERK
To elucidate the mode of anti-osteoclastogenic action of
matairesinol, we investigated whether matairesinol can
affect the activation of RANKL-induced early signaling
pathways. As shown in Figure 4, RANKL strongly in-
duced the phosphorylation of p38 and ERK, but mataire-
sinol dramatically inhibited those inductions. Our results
suggest that inhibition of p38 and ERK phosphorylation
could contribute to the anti-osteoclastogenic action of
matairesinol.
Matairesinol has no effect on survival and resorptive
activity of mature osteoclasts
To investigate whether matairesinol can affect the sur-
vival and resorptive activity of mature osteoclasts, weition of osteoclast differentiation. (A) BMMs were infected with
with polybrene (10 μg/ml). Infected BMMs were cultured with M-CSF
matairesinol (10 μM). After 4 days, cells were fixed and GFP expression
FP or CA-NFATc1-GFP, and cells were cultured as described in (A).
ed by TRAP staining. (C) TRAP-positive cells were counted as
Figure 4 Matairesinol inhibits RANKL-induced
phosphorylation of p38 and ERK. In the condition of serum
starvation for 2 h, BMMs were pretreated with vehicle or
matairesinol (10 μM) for 1 h prior to RANKL stimulation (10 ng/ml) at
the indicated time periods. Protein expression levels were then
evaluated by Western blot analysis. Actin was used as the
internal control.
Figure 5 Matairesinol did not affect survival or anti-resorptive act
plated on BioCoat slides and treated for 24 h with the indicated conce
with TRAP, and photographed under a light microscope. TRAP-positive
Osteologic MultiTest slides were removed and photographed under a
program.
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assay with purified mature osteoclasts in the presence or
absence of matairesinol. When purified mature osteo-
clasts from co-culture were re-plated on carbonate
apatite-coated plates and cultured in the presence or ab-
sence of matairesinol for 1 day, matairesinol did not
show any cytotoxicity and did not affect the number of
TRAP-positive multinucleated cells (Figure 5A). Further-
more, the addition of matairesinol did not significantly
change the resorptive activity of mature osteoclasts;
matairesinol-treated osteoclasts resorbed the carbonate
apatite-coated plates similarly to untreated control oste-
oclasts (Figure 5B). These results indicated that mataire-
sinol did not affect the survival and bone-resorptive
activity of mature osteoclasts.
Discussion
Osteoclasts are present only in bone, where they play an
essential role in bone resorption. Intervention in osteo-
clast differentiation and its function has been postulated
as a treatment for bone metabolic diseases such as
osteoporosis [15].
RANKL signaling triggers osteoclast differentiation
and has been an important target for treating patho-
logical bone loss. Docking of RANKL to its receptor,
RANK, rapidly activates MAP kinases such as p38, ERK,
and JNK. These MAP kinases are essential for theivity of mature osteoclasts. (A) Mature osteoclasts were
ntrations of matairesinol. Cells were fixed, permeabilized, stained
multinucleated cells were counted. (B) Attached cells on BioCoat
light microscope. Pit areas were quantified using the ImageJ
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[16-18]. Activated MAP kinases then lead to the stimula-
tion of transcription factors such as NFATc1.
NFATc1 is a master regulator of osteoclast differenti-
ation. The expression of NFATc1 is strongly up-regulated
during RANKL-induced osteoclastogenesis. The overex-
pression of NFATc1 accelerates RANKL-induced osteo-
clast differentiation, and transduced-NFATc1 increased
osteoclast formation even without stimulation with
RANKL; in contrast, NFATc1-deficent embryonic stem
cells fail to differentiate into osteoclasts even in the pres-
ence of RANKL [19]. In this study, we found that mataire-
sinol strongly attenuated RANKL-induced osteoclast
differentiation with suppression of NFATc1 expression.
The inhibitory effect of matairesinol via downregulation of
NFATc1 was confirmed by evaluating the mRNA expres-
sion levels of NFATc1-dependent genes such as TRAP,
OSCAR, and v-ATPasev0d2. NFATc1 induces the expres-
sion of TRAP and OSCAR during osteoclast differenti-
ation [20] and plays a role in the process of osteoclast
multinucleation through induction of Atp6v0d2 [21]. The
results of the NFATc1 overexpression experiment also
confirmed the involvement of NFATc1 in the anti-
osteoclastogenic action of matairesinol. The matairesinol-
mediated inhibition of osteoclast differentiation was
almost rescued by the ectopic expression of NFATc1.
As mentioned above, during osteoclastogenesis, MAP
kinases regulate NFATc1. In particular, Huang et al. [22]
reported the RANKL-dependent role of p38 in modulating
NFATc1 expression during osteoclastogenesis. Further-
more, the involvement of the ERK pathway in osteoclast
differentiation has received much attention; ERK can trig-
ger activation of c-Fos-NFATc1 for osteoclastogenesis, and
the inhibition of ERK suppresses osteoclast formation and
function [23]. Likewise, pharmacologic inhibition studies
have suggested the importance of p38 and ERK signaling
in osteoclastogenesis [24]. Therefore, modulation of p38
and ERK could control RANKL-mediated osteoclast dif-
ferentiation via NFATc1-dependent transcription. In this
study, matairesinol suppressed RANKL-induced activation
of p38 and ERK. Taken together with the inhibitory activ-
ity of matairesinol in downregulating NFATc1, its anti-
osteoclastogenic activity could result from its potential to
inhibit RANKL-induced activation of p38 and ERK
signaling.
Of importance, numerous drugs targeting the resorp-
tive action of osteoclasts including bisphosphonate, ca-
thepsin K inhibitors, and src inhibitors, are currently
available or under clinical examination to treat bone
metabolic diseases [25], and several phytochemicals with
anti-osteoclastogenic activity also inhibit the survival
and/or the resorptive activity of mature osteoclasts
[26,27]. For this reason, we further evaluated the anti-
resorptive activity of matairesinol, but found that it didnot affect survival and bone resorptive activity of mature
osteoclasts. These results suggested that matairesinol with
anti-osteoclastogenic activity via the down-regulation of
the p38/ERK-NFATc1 signaling axis might not be enough
to inhibit the survival and function of mature osteoclasts.
Conclusions
To our knowledge, this study is the first to report the anti-
osteoclastogenic activity of matairesinol: It is associated
with downregulation of p38, ERK, and NFATc1, which
consequently leads to the decreased expression of genes
required for osteoclastogenesis such as TRAP, OSCAR,
and v-ATPasev0d2. Although matairesinol did not inhibit
the survival and bone resorptive activity of mature osteo-
clasts, it could be useful for preventing osteoclastogenesis-
related bone metabolic diseases including osteoporosis,
rheumatoid arthritis and periodontal disease.
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